ICU Medical (NASDAQ:ICUI) Upgraded at StockNews.com

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a report published on Friday morning.

Several other research firms have also recently weighed in on ICUI. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research report on Wednesday, December 11th. Raymond James set a $97.00 price target on ICU Medical in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ICU Medical presently has an average rating of “Buy” and a consensus price target of $168.67.

ICU Medical Trading Down 1.6 %

ICUI opened at $139.32 on Friday. The stock has a market capitalization of $3.42 billion, a P/E ratio of -30.49 and a beta of 0.86. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical has a 12 month low of $93.36 and a 12 month high of $196.26. The firm’s fifty day simple moving average is $151.64 and its 200 day simple moving average is $162.46.

Institutional Trading of ICU Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in ICU Medical by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after purchasing an additional 17,805 shares in the last quarter. State Street Corp grew its stake in shares of ICU Medical by 9.3% in the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after buying an additional 77,506 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in ICU Medical by 7.4% during the fourth quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock worth $109,920,000 after buying an additional 49,108 shares during the last quarter. Geode Capital Management LLC raised its position in ICU Medical by 9.6% during the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after acquiring an additional 48,106 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in ICU Medical by 18.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock valued at $83,788,000 after acquiring an additional 82,982 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.